News

FDA Awards Nearly $3 Million for TB Research


10 Oct 2010
by Working Group

This post originally appeared on Science Speaks.

US Food and Drug Administration
US Food and Drug Administration

The U.S. Food and Drug Administration (FDA) announced $2.9 million to support six research projects related to the diagnosis, treatment and prevention of tuberculosis on Monday.

This investment is a component of the FDA’s Critical Path Initiative (CPI) — a national strategy for transforming the way FDA-regulated products are developed, evaluated and manufactured. FDA launched the CPI in 2004 to address the decline in the number of innovative medical products being submitted for approval. One of the areas of CPI focus is new efforts to help meet unmet global public health needs. Beginning in 2010, CPI launched a new project aimed at enhancing the development and availability of diagnostics and therapies for tropical diseases, especially tuberculosis.

On March 19th, FDA Commissioner Hamburg and others announced a new collaboration to accelerate the development of combination treatments for tuberculosis. More information about the announcement can be found on the TB Alliance’s Critical Path to TB Regimens page.

Monday’s announcement includes grant awards made in the areas of TB vaccines, drugs and diagnostics.

More News
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...
3 Aug 2023
The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
23 Aug 2022
The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...